2026年11月4日星期三
M
Catatan Universal
Berita Kilat Global
Ethics drive Wardah to pinnacle of Southeast Asia's beauty brands— 日经 Nikkei AsiaCyber insurance inquiries surge at Japan's nonlife insurers— 日经 Nikkei AsiaSingapore's Insignia Ventures backs rural Japan for Davos-inspired academy— 日经 Nikkei AsiaThe great yen rebalancing— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaNorth Korea leans on China and Russia to drive 3% economic growth— 日经 Nikkei AsiaJapan's IHI wins key role in Westinghouse's new Poland nuclear plant— 日经 Nikkei AsiaUS experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaEthics drive Wardah to pinnacle of Southeast Asia's beauty brands— 日经 Nikkei AsiaCyber insurance inquiries surge at Japan's nonlife insurers— 日经 Nikkei AsiaSingapore's Insignia Ventures backs rural Japan for Davos-inspired academy— 日经 Nikkei AsiaThe great yen rebalancing— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaNorth Korea leans on China and Russia to drive 3% economic growth— 日经 Nikkei AsiaJapan's IHI wins key role in Westinghouse's new Poland nuclear plant— 日经 Nikkei AsiaUS experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei Asia

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Sumber Nature 医学研究1 hari lalu
Ringkasan konten

Situs ini hanya menyediakan indeks judul dan ringkasan, konten lengkap dan hak cipta sepenuhnya milik penerbit asli, silakan klik tautan asli untuk membaca.

Buka artikel asli
Saluran terkait
Kesehatan
Wilayah terkait
Perspektif global
Bahasa asli
English
Nomor entri
health-00a74bed

Comments 0 comments

No comments yet. Be the first.

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials · Catatan Universal